In vitro antifungal susceptibility of clinically relevant species belonging to Aspergillus section Flavi

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1944-1947

  Gonçalves, Sarah S ^a   Stchigel, Alberto M ^b   Cano, Josep ^b   Guarro, Josep ^b   Colombo, Arnaldo L ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN; POSACONAZOLE; TERBINAFINE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; BROTH DILUTION; CLADISTICS; CONTROLLED STUDY; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; ECHINOCANDINS; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES; PHYLOGENY; TRIAZOLES;

EID: 84875138025     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01902-12     Document Type: Article

References (25)

1. Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP, Ito JI, Balajee SA, Pappas PG, Moser SA. 2009. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J. Clin. Microbiol. 47:3271-3275.
2. Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, Fridkin SK, Pappas PG, Warnock DW. 2005. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med. Mycol. 43(Suppl 1):S49-S58.
3. Hedayati MT, Pasqualotto AC, Warn PA, Bowyer P, Denning DW. 2007. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 153:1677-1692.
4. Pasqualotto AC. 2008. Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Med. Mycol. 47:(Suppl 1):S261-S270.
5. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
6. Stratov I, Korman TM, Johnson PD. 2003. Management of Aspergillus osteomyelitis: report of failure of liposomal amphotericin B and response to voriconazole in an immunocompetent host and literature review. Eur. J. Clin. Microbiol. Infect. Dis. 22:277-283.
7. Verweij PE, Mellado E, Melchers WJ. 2007. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356:1481-1483.
8. Snelders E, van der Lee HAL, Kuijpers J, Rijs AJ, Varga J, Samson RA, Mellado E, Donders AR, Melchers WJ, Verweij PE. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219. doi:10.1371/journal.pmed.0050219.
9. Gonçalves SS, Stchigel AM, Cano JF, Godoy-Martinez PC, Colombo AL, Guarro J. 2012. Aspergillus novoparasiticus: a new clinical species of the section. Med. Mycol. 50:152-160.
10. Akiyama K, Takizawa H, Suzuki M, Miyachi S, Ichinohe M, Yanagihara Y. 1987. Allergic bronchopulmonary aspergillosis due to Aspergillus oryzae. Chest 91:285-286.
11. Kredics L, Varga J, Kocsubé S, Dóczi I, Samson RA, Rajaraman R, Narendran V, Bhaskar M, Vágvölgyi C, Manikandan P. 2007. Case of keratitis caused by Aspergillus tamarii. J. Clin. Microbiol. 45:3464-3467.
12. Manikandan P, Varga J, Kocsubé S, Samson RA, Anita R, Revathi R, Dóczi I, Németh TM, Narendran V, Vágvölgyi C, Manoharan C, Kredics L. 2009. Mycotic keratitis due to Aspergillus nomius. J. Clin. Microbiol. 47:3382-3385.
13. Geiser DM, Dorner JW, Horn BW, Taylor JW. 2000. The phylogenetics of mycotoxin and sclerotium production in Aspergillus flavus and Aspergillus oryzae. Fungal Genet. Biol. 31:169-179.
14. Gonçalves SS, Cano JF, Stchigel AM, Melo AS, Godoy-Martinez PC, Correa B, Guarro J. 2012. Molecular phylogeny and phenotypic variability of clinical and environmental strains of Aspergillus flavus. Fungal Biol. 116:1146-1155.
15. Gilgado F, Cano J, Gene J, Guarro J. 2005. Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species. J. Clin. Microbiol. 43:4930-4942.
16. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Paludetti G, Rosignoli M, Ferri E, Cesari MR, Morace G, Fantoni M, Galli J. 1992. Invasive nasosinusal aspergillosis in an immunocompetent patient. Acta Otorhinolaryngol. Ital. 12:581-591. (In Italian.)
18. Kristensen L, Stenderup J, Otkjaer A. 2005. Onychomycosis due to Aspergillus tamarii in a 3-year-old boy. Acta Derm. Venereol. 85:261-262.
19. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. 2006. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 50:917-921.
20. Gomez-Lopez A, Garcia-Effron G, Mellado E, Monzon A, Rodriguez-Tudela JL, Cuenca-Estrella M. 2003. In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 47:3085-3088.
21. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
22. Guinea J, Peláez T, Alcalá L, Ruiz-Serrano MJ, Bouza E. 2005. Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation. Antimicrob. Agents Chemother. 49:3495-3497.
23. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. 2003. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. 41:3623-3626.
24. Lass-Flörl C, Kofler G, Kropshofer G, Hermans J, Kreczy A, Dierich MP, Niederwieser D. 1998. In vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J. Antimicrob. Chemother. 42:497-502.
25. Krishnan-Natesan S. 2009. Terbinafine: a pharmacological and clinical review. Expert. Opin. Pharmacother. 10:2723-2733.